Search

Displaying results 4661 - 4670 of 9889 in total
  1. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … PLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC

  2. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).

    Synonyms: hOKT3 γ1(Ala-Ala), hOKT3 gamma1(Ala-Ala)
  3. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  4. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in th...

  5. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo. … Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>).

  6. Drug

    Imolamine

    go.drugbank.com/drugs/DB09284
    Investigational

    Imolamine is a compound with a molecular weight of 260.33 g/mol with the formula diethyl[2-{5-imino-3-phenyl-4,5-dihydro-1,2,3-oxadiazol,-4-yl)ethyl]amine. … It is developed under the brand name Coremax by Novartis consumer health SA.

  7. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. … favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  9. Drug

    SX-682

    go.drugbank.com/drugs/DB19210
    Investigational

    clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1

  10. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental